---
title: "Vaccinex to delist its common stock from Nasdaq after trading suspended since Dec 18, 2024."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/232022602.md"
description: "In Rochester, New York, on March 07, 2025, Vaccinex, Inc. (OTC: VCNX) revealed its plan to delist its common stock from Nasdaq. The clinical-stage biotechnology company specializes in a unique approach to managing neurodegenerative diseases by targeting astrogliosis and neuroinflammation via SEMA4D inhibition. Following suspension from Nasdaq trading since December 18, 2024, the Company officially informed Nasdaq of its delisting decision. The common stock in question holds a par value of $0.0001 per share."
datetime: "2025-03-17T04:07:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/232022602.md)
  - [en](https://longbridge.com/en/news/232022602.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/232022602.md)
generator: "portal-rs"
---

# Vaccinex to delist its common stock from Nasdaq after trading suspended since Dec 18, 2024.

In Rochester, New York, on March 07, 2025, Vaccinex, Inc. (OTC: VCNX) revealed its plan to delist its common stock from Nasdaq. The clinical-stage biotechnology company specializes in a unique approach to managing neurodegenerative diseases by targeting astrogliosis and neuroinflammation via SEMA4D inhibition. Following suspension from Nasdaq trading since December 18, 2024, the Company officially informed Nasdaq of its delisting decision. The common stock in question holds a par value of $0.0001 per share.

### Related Stocks

- [VCNX.US](https://longbridge.com/en/quote/VCNX.US.md)

## Related News & Research

- [Live Nation Entertainment (LYV) Expands Venues As Investors Weigh Its Valuation](https://longbridge.com/en/news/305560320.md)
- [How Investors Are Reacting To Nurix Therapeutics (NRIX) CMO Appointment](https://longbridge.com/en/news/305560504.md)
- [Tango Therapeutics (TNGX) Climbed, So What Is Driving Attention Now?](https://longbridge.com/en/news/305573939.md)
- [GE HealthCare Technologies (GEHC) Tests Its Brain Imaging Narrative As Undervalued View Holds](https://longbridge.com/en/news/305561290.md)
- [Missed Viasat's 88% Gain? Here's What Investors Got Right](https://longbridge.com/en/news/305561187.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**